Sotorasib(Lumakras)

The original manufacturer of Sotorasib is Amgen Corporation of the United States, which received accelerated approval from the FDA for listing on May 28, 2021.

The version of Sotolasib produced by Lucius has a specification of 120mg*56 tablets.

Sotorasib is a covalent inhibitor specifically targeting the KRASG12C mutant, and as a targeted therapeutic drug for non-small cell lung cancer with KRASG12C mutation, it has significant clinical efficacy.

1.Main components

Sotorasib

2.Adapt to the population

Adult patients with non-small cell lung cancer.

3.Medication for special populations

3.1Pregnant women and lactation period

Pregnant women should take medication according to the doctor's advice, and it is recommended that lactating women do not breastfeed during the treatment period and for one week after the final dose of sotoraxib.

3.2Geriatric Use

Elderly people need to take medication according to the doctor's advice.

3.3Pediatric Use

The safety and efficacy of sotoraxib in children have not been confirmed, so pediatric patients need to be cautious when using it.

4.Drug overdose

Drug overdose is not yet clear.

5.Drug storage

Store at 20℃ to 25℃ (68℉ to 77℉). Excursions permitted from 15℃ to 30℃(59℉ to 86℉).

6.Pharmacokinetics

The median time to sotorasib peak plasma concentration is 1 hour. 

from FDA，2023.04